Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant palbociclib + letrozole in HR-positive/HER2-negative early breast cancer with intermediate or high Oncotype DX recurrence score
2018-001702-28Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib and letrozole in breast cancer, sponsored by MEDSIR. Primary endpoints: Stable post-treatment recurrence score in cohort A and Global molecular changes measured by post-treatment recurrence score or pathological complete response. Started Oct 2018; status: completed.
02
Drugs
palbociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-001702-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001702-28.